Intravitreal injections of anti-vascular endothelial growth factor (VEGF) have become increasingly popular in the treatment of ocular illness such as neovascular age-related degeneration (nAMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion in recent years. This evidence concerns the gene VEGFA and retinal vein occlusion.